ProCE Banner Activity

CE

Integrating BCMA-Targeted Therapies Into R/R Multiple Myeloma Care: Opportunities for Pharmacists

Video

Watch this on-demand webcast featuring expert presentations and discussion on the latest developments in BCMA-targeted therapies for multiple myeloma, including CAR T-cells, bispecific antibodies, and practical considerations for administration and monitoring.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: June 14, 2023

Expiration: June 13, 2024

No longer available for credit.

Share

Faculty

Donald C. Moore

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

Victoria Nachar

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC and the Hematology/Oncology Pharmacy Association (HOPA)

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Partners

Clinical Care Options, LLC

ProCE Banner

Hematology/Oncology Pharmacy Association (HOPA)

ProCE Banner

Target Audience

The target audience is pharmacists who care for patients with R/R MM disease state as well as other stakeholders in hematology/oncology practice.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners in applying practice-changing clinical data and expert recommendations to integrate the use of BCMA-targeted agents for their patients with R/R MM.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the treatment role of novel BCMA-targeted therapies, including antibody–drug conjugates, bispecifics, and CAR T-cell therapy, in R/R MM

  • Select personalized, evidence-based treatment regimens with BCMA-targeted therapies considering available efficacy, safety, and tolerability data along with guideline and expert recommendations, patient preference, disease prognosis, and functional status

  • Monitor and mitigate potential adverse events from anti-BCMA therapy, including but not limited to ocular toxicity, cytokine-release syndrome, and neurotoxicity

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP

Clinical Oncology Pharmacy Manager
Atrium Health Levine Cancer Institute
Charlotte, North Carolina

Donald C. Moore, PharmD, BCPS, BCOP, DPLA, FCCP: consultant/advisor/ speaker: AstraZeneca, Janssen, Pfizer.

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Victoria Nachar, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC have no relevant financial relationships to disclose.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacists

A picture containing text, window, clipartDescription automatically generatedThis activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-010-H01-P has been assigned to this home study application-based activity. This activity is approved for 1 contact hour (0.1 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.